High circ_100053 predicts a poor outcome for chronic myeloid leukemia and is involved in imatinib resistance

Lei Ping; Chen Jian-Jun; Liao Chu-Shu; Liu Guang-Hua; Zhou Ming

doi:10.3727/096504018X15412701483326

High circ_100053 predicts a poor outcome for chronic myeloid leukemia and is involved in imatinib resistance

Oncol Res. 2019 Feb 14. doi: 10.3727/096504018X15412701483326. Online ahead of print.

Authors

Lei Ping¹, Chen Jian-Jun², Liao Chu-Shu¹, Liu Guang-Hua¹, Zhou Ming²

Affiliations

¹ Laboratory of Hematology, Hunan Provincial People's Hospital, The First-Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, China, 410002.
² Department of Hematology, Hunan Provincial People's Hospital, The First-Affiliated Hospital of Hunan Normal University, Changsha, Hunan Province, China, 410002.

PMID: 30764894
DOI: 10.3727/096504018X15412701483326

Abstract

Chronic myeloid leukemia (CML) is a rare clonal myeloproliferative malignancy, which is caused by a reciprocal translocation between chromosomes 9 and 22 t(9;22) (q34;q11). Altered circle RNAs (circRNAs) could contribute to leukemogenesis. In this study, we aimed to investigate the expression profiling of circRNAs in CML. We performed circRNA-sequencing to identify differentially expressed circRNAs in CML cells. Furthermore, we found that circ_100053 was significantly upregulated in peripheral blood mononuclear cells (PBMC) and serum samples from CML compared with healthy controls. CircRNA_100053 expression was associated with clinical stage (p=0.037) and BCR/ABL mutant status (p=0.008). High circ_100053 expression predicted a poor outcome of CML patients and imatinib resistance, suggesting the putative role of circ_100053 as an CML biomarker. Our findings provide insights on circRNAs expression in the development and treatment of CML.